Compare Crispr Therapeutics AG (CRSP) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Crispr Therapeutics AG trades at $50.47 (market cap $4.97B), while Direxion Daily Semiconductor Bear 3X Shares trades at $47.92. Which is the better fit depends on your goals.
| CRSP | SOXS | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $1.61K |
52-Week Low | $44.34 | $32.50 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $46.65, up 14.34% on the day amid semiconductor sector volatility. Technical indicators show a neutral overall signal with bearish moving averages. The ETF is scheduled for a 1:10 stock split on July 15, 2026, and declared a $0.04 dividend for H1-2026. Recent news highlights the ETF's role in betting against the AI-driven semiconductor rally, with SOXS down significantly over six months as chip stocks surge.
The outlook for SOXS remains highly speculative, offering leveraged inverse exposure to semiconductors. Key opportunities include hedging against a potential semiconductor downturn, but risks are extreme due to the ETF's bearish structure in a strong bull market. Volatility decay and the sector's momentum pose substantial threats to long-term holders, making it suitable only for tactical, short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
